Movement Alert｜Novo Nordisk Rises 3.31% in Pre-Market Trading, CEO Announces Plan to File Oral Wegovy for Chinese Approval

Market Focus06-17 19:03

On June 17, Novo Nordisk rose 3.31% in pre-market trading, trading at $45.06/share, with turnover of $5.48 million.

The move was driven by Novo Nordisk's global CEO Mike Doustdar announcing during his first visit to China since taking the role that the company plans to submit clinical data for its oral version of Wegovy to Chinese regulators within months, seeking marketing approval for the weight-loss pill. The CEO stated the company aims to catch up with Eli Lilly, which submitted a marketing application for its oral obesity drug in China late last year.

Doustdar also indicated that Novo Nordisk expects generic semaglutide competition to emerge beginning in Q2 2027, noting that while the semaglutide patent expired in China in March, the company retains regulatory data protection through early next year. He further signaled that BD deals in China would increase, stating the company is in active dialogue with multiple Chinese firms. Separately, oral Wegovy recently received UK regulatory approval as the first European market, with clinical data showing 13.6% average weight loss after 64 weeks.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

1

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1145096563?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-17 19:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1145096563","market":"us","top_or_hot":-1,"title":"Movement Alert｜Novo Nordisk Rises 3.31% in Pre-Market Trading, CEO Announces Plan to File Oral Wegovy for Chinese Approval","media":"Market Focus","content":"<p><p>On June 17, Novo Nordisk rose 3.31% in pre-market trading, trading at $45.06/share, with turnover of $5.48 million.</p><p>The move was driven by Novo Nordisk's global CEO Mike Doustdar announcing during his first visit to China since taking the role that the company plans to submit clinical data for its oral version of Wegovy to Chinese regulators within months, seeking marketing approval for the weight-loss pill. The CEO stated the company aims to catch up with Eli Lilly, which submitted a marketing application for its oral obesity drug in China late last year.</p><p>Doustdar also indicated that Novo Nordisk expects generic semaglutide competition to emerge beginning in Q2 2027, noting that while the semaglutide patent expired in China in March, the company retains regulatory data protection through early next year. He further signaled that BD deals in China would increase, stating the company is in active dialogue with multiple Chinese firms. Separately, oral Wegovy recently received UK regulatory approval as the first European market, with clinical data showing 13.6% average weight loss after 64 weeks.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Novo Nordisk Rises 3.31% in Pre-Market Trading, CEO Announces Plan to File Oral Wegovy for Chinese Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Novo Nordisk Rises 3.31% in Pre-Market Trading, CEO Announces Plan to File Oral Wegovy for Chinese Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-17 19:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 17, Novo Nordisk rose 3.31% in pre-market trading, trading at $45.06/share, with turnover of $5.48 million.</p><p>The move was driven by Novo Nordisk's global CEO Mike Doustdar announcing during his first visit to China since taking the role that the company plans to submit clinical data for its oral version of Wegovy to Chinese regulators within months, seeking marketing approval for the weight-loss pill. The CEO stated the company aims to catch up with Eli Lilly, which submitted a marketing application for its oral obesity drug in China late last year.</p><p>Doustdar also indicated that Novo Nordisk expects generic semaglutide competition to emerge beginning in Q2 2027, noting that while the semaglutide patent expired in China in March, the company retains regulatory data protection through early next year. He further signaled that BD deals in China would increase, stating the company is in active dialogue with multiple Chinese firms. Separately, oral Wegovy recently received UK regulatory approval as the first European market, with clinical data showing 13.6% average weight loss after 64 weeks.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"","article_id":"1145096563","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1145096563","pubTimestamp":1781694215,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 17, Novo Nordisk rose 3.31% in pre-market trading, trading at $45.06/share, with turnover of $5.48 million.The move was driven by Novo Nordisk's global CEO Mike Doustdar announcing during his...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德"},"translate_title":"动向提示|诺和诺德盘前涨3.31%CEO宣布拟将口服Wegovy提交中国审批","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"On June 17, Novo Nordisk rose 3.31% in pre-market trading, trading at $45.06/share, with turnover of $5.48 million.The move was driven by Novo Nordisk's global CEO Mike Doustdar announcing during his first visit to China since taking the role that the company plans to submit clinical data for its oral version of Wegovy to Chinese regulators within months, seeking marketing approval for the weight-loss pill. The CEO stated the company aims to catch up with Eli Lilly, which submitted a marketing application for its oral obesity drug in China late last year.Doustdar also indicated that Novo Nordisk expects generic semaglutide competition to emerge beginning in Q2 2027, noting that while the semaglutide patent expired in China in March, the company retains regulatory data protection through early next year. He further signaled that BD deals in China would increase, stating the company is in active dialogue with multiple Chinese firms. Separately, oral Wegovy recently received UK regulatory approval as the first European market, with clinical data showing 13.6% average weight loss after 64 weeks.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1145096563","isCrawlerRequest":true}